Evaluating Immunome: Insights From 4 Financial Analysts

In the preceding three months, 4 analysts have released ratings for Immunome (NASDAQ:IMNM), presenting a wide array of perspectives from bullish to bearish.The following table provides a quick overvie

BenzingaMay 31 09:00 ET

Immunome Initiated at Overweight by Piper Sandler

Immunome Initiated at Overweight by Piper Sandler

Dow JonesMay 31 06:09 ET

Express News | Piper Sandler Initiates Coverage On Immunome With Overweight Rating, Announces Price Target of $27

BenzingaMay 31 05:58 ET

Immunome Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/31/2024 87.5% Piper Sandler → $27 Initiates Coverage On → Overweight 04/30/2024 66.67% JP Morgan → $24

BenzingaMay 31 05:56 ET

Bullish Immunome Insiders Loaded Up On US$2.67m Of Stock

Over the last year, a good number of insiders have significantly increased their holdings in Immunome, Inc. (NASDAQ:IMNM). This is encouraging because it indicates that insiders are more optimistic ab

Simply Wall StMay 29 07:58 ET

Immunome (NASDAQ:IMNM): An Opportunity for Investors With Strong Stomachs

TipRanksMay 24 13:14 ET